Synonyms: example 117 [WO2019090158A1]
Compound class:
Synthetic organic
Comment: The structure for lepzacitinib was obtained from proposed INN list 129 (August 2023) where it is described as a Janus kinase inhibitor and anti-inflammatory agent. It is one of the compounds claimed in patent WO2019090158A1 [1]. Aclaris have three JAK inhibitors in their development pipeline, two of which are in clinical assessment: ATI-1777 (a soft inhibitor for topical applications such as atopic dermatitis), and ATI-2138 (a dual ITK/JAK3) inhibitor for T cell-mediated autoimmune diseases. Lepzacitinib is most likely ATI-1777.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
ethyl 4-[[(3R)-1-(2-cyanoacetyl)piperidin-3-yl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxylate |
Synonyms |
example 117 [WO2019090158A1] |
Database Links | |
BindingDB Ligand | 493018 |
CAS Registry No. | 2321488-47-3 (source: WHO INN record) |
GtoPdb PubChem SID | 485205992 |
PubChem CID | 138624627 |
Search Google for chemical match using the InChIKey | QQOPOYMFJLUSBI-GFCCVEGCSA-N |
Search Google for chemicals with the same backbone | QQOPOYMFJLUSBI |
UniChem Compound Search for chemical match using the InChIKey | QQOPOYMFJLUSBI-GFCCVEGCSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | QQOPOYMFJLUSBI-GFCCVEGCSA-N |